相关实验视频

Updated: Jan 7, 2026

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Published on: April 12, 2024

与m5C相关的调节器定义瘤微环境,并预测肝细胞癌的预后

Xiang-Qian Gu¹, Bin Li¹, Cheng-Yu Gu¹

¹Department of Hepatobiliary Surgery, Wuxi People's Hospital Affiliated Nanjing Medical University, Wuxi, China.

Asian Pacific journal of cancer prevention : APJCP

|December 29, 2025

概括

这项研究确定了包括NSUN3,NSUN5和YBX1在内的关键RNA5-甲基细胞因 (m5C) 调节器,对于肝细胞癌 (HCC) 预后和瘤免疫微环境 (TIME) 至关重要. 一个新的风险模型预测了HCC患者的生存率和治疗潜力.

科学领域:

在瘤学瘤学.
表观遗传学在表观遗传学中,表观遗传学是指表观遗传学.
免疫学免疫学免疫学

背景情况:

肝细胞癌 (HCC) 是一种具有高死亡率的全球致命癌症.
RNA5-甲基细胞因 (m5C) 修饰是一种重要的表观遗传调节剂,但其在HCC预后和瘤免疫微环境 (TIME) 中的作用尚不清楚.

研究的目的:

调查m5CRNA甲基化调节剂在HCC中的预后价值.
探索m5C调节器与HCC中的TIME之间的关联.
开发基于m5C调节器的HCC患者的预后模型.

主要方法:

利用来自TCGA和ICGC数据库的RNA测序和临床数据.
应用无监督聚类来识别m5C调节器子组和生存分析.
使用考克斯回归构建了一个预后模型,并验证了它的性能.

主要成果:

根据m5C调节器确定了三种不同的HCC分子子组,与生存和免疫透有关.
开发了一个预后特征 (NSUN3,NSUN5,YBX1),将患者分为高风险和低风险组,具有差异性的整体存活率 (OS).
验证了风险模型,并确认了其作为预后因素的独立性,当与临床病理特征相结合时.

结论:

m5C 调节器在 HCC 的 TIME 中起着重要的作用.
已识别的m5C调节器和开发的风险模型为HCC患者提供了预后价值和潜在的治疗目标.

关键词:

肝细胞癌是肝细胞癌.瘤微环境瘤微环境免疫透免疫透是什么?m5C 的甲基化.预后签名预测签名

更多相关视频

Mass Cytometry Analysis of Systemic and Local Immune Responses in Hepatocellular Carcinoma

Mass Cytometry Analysis of Systemic and Local Immune Responses in Hepatocellular Carcinoma

Published on: April 25, 2025

Analyzing Tumor Gene Expression Factors with the CorExplorer Web Portal

Analyzing Tumor Gene Expression Factors with the CorExplorer Web Portal

Published on: October 11, 2019

相关概念视频

The Tumor Microenvironment

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

Master Transcription Regulators

Master Transcription Regulators

Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...